ALCYONE LIFESCIENCES

Alcyone Lifesciences develops a platform of technology that optimizes molecular therapy for the brain. It addresses the unmet needs in the treatment of chronic neuropathological conditions. For many neurologic conditions, there are identified molecular targets, but the blood-brain barrier prevents drugs from addressing those targets from reaching diseased brain regions in a controlled and targeted manner. In addition, there is a fundamental need for control and precision in molecular therapy to the CNS. The company is transforming disease-modifying therapies for rare and orphan disorders through Advanced Precision Delivery Platforms.